Develop better pharmaceutical obesity therapies
Obesity drug sales are forecast to $3.8bn globally in 2018 [2]—in comparison to $57bn for Diabetes drug sales[2]—with evidence suggesting that the modest average weight losses achieved with current anti-obesity agents may be of some clinical benefit [5]. However, the current generation of drugs, which act on the central nervous system to suppress appetite, have raised significant health concerns—including psychiatric disorders, such as suicidal behaviour, depression, and cardiovascular problems.

​​Cost-effective interventions to reduce obesity in the UK

​​

Immediately related elementsHow this works
-
Tackling obesity in the UK »Tackling obesity in the UK
Tackling obesity »Tackling obesity
Improve the costs and outcomes of medical interventions »Improve the costs and outcomes of medical interventions
Develop better pharmaceutical obesity therapies
Over-the-counter pharmaceuticals »Over-the-counter pharmaceuticals
Prescription pharmaceuticals »Prescription pharmaceuticals
Actions – Industry »Actions – Industry
Surgical and pharmaceutical solutions don't resolve societal problems »Surgical and pharmaceutical solutions don't resolve societal problems
08. Pharmaceuticals »08. Pharmaceuticals
+Komentarai (0)
+Citavimą (6)
+About